Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,292 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Period 2 treatment Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Characterize Pharmacokinetics (PK) and Pharmacodynamics (PD) of LUSEDRA® Administered as Continuous Infusion or Bolus Compared With Continuous Infusion of Propofol Injectable Emulsion

NCT01308541
View directory record Official record
Conditions
Monitored Anesthesia Care
Interventions
arm 1, LUSEDRA, Propofol (arm 3)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Salt Lake City Utah, Utah
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Sep 5, 2026, 10:54 AM EDT
Recruiting Not applicable Interventional

Healthy Lifestyles for Bipolar Disorder

NCT06188754
View directory record Official record
Conditions
Time Restricted Eating, Diet, Mediterranean
Interventions
Time restricted eating, Mediterranean diet
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 5, 2026, 10:54 AM EDT
Completed Not applicable Interventional

Neurostimulation for Cognitive Enhancement in Alzheimer's Disease

NCT04404153
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver active tDCS., tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver sham tDCS.
Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 5, 2026, 10:54 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 5, 2026, 10:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Online Intervention to Promote Resilience to Traumatic Stress During Pregnancy

NCT04992767
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Pregnancy Related
Interventions
Sunnyside, SunnysideFlex
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Sep 5, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

Bonipar for Acute and Chronic Musculoskeletal Pain

NCT03471507
View directory record Official record
Conditions
Chronic Pain, Musculoskeletal Pain
Interventions
Bonipar, Diclofenac sodium topical solution 1.5%
Drug
Lead sponsor
Winston Parris, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Sep 5, 2026, 10:54 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

NCT03838484
View directory record Official record
Conditions
Schizophrenia, Impulsive Behavior
Interventions
Nicotine Patch, 7 Mg/24 Hr, Placebo patch
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 5, 2026, 10:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PREDICT 2: Personalized Responses to Dietary Composition Trial 2

NCT03983733
View directory record Official record
Conditions
Diabetes, Heart Diseases, Diet Habit, Diet Modification, Microbial Colonization, Healthy, Obesity, Metabolism
Interventions
Dietary Intervention
Other
Lead sponsor
Zoe Global Limited
Other
Eligibility
18 Years to 70 Years
Enrollment
1,139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 5, 2026, 10:54 AM EDT
Completed Phase 4 Interventional

Risankizumab Long-term Remission Study

NCT04630652
View directory record Official record
Conditions
Psoriasis
Interventions
Risankizumab-Rzaa, Punch biopsies of the skin at baseline visit, Punch biopsies of the skin at week 28 visit
Drug · Procedure
Lead sponsor
Jaehwan Kim
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Sacramento, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 5, 2026, 10:54 AM EDT
Completed Phase 3 Interventional Results available

MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines

NCT03732833
View directory record Official record
Conditions
Lateral Canthal Lines, Glabellar Lines
Interventions
MT10109L, Placebo
Drug
Lead sponsor
Medy-Tox
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
11
States / cities
Scottsdale, Arizona • Solana Beach, California • Bradenton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 5, 2026, 10:54 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Low-calorie Diet in Isolated Impaired Fasting Glucose

NCT06451055
View directory record Official record
Conditions
Isolated Impaired Fasting Glucose
Interventions
Low-calorie diet, Routine dietary and physical activity habits
Behavioral
Lead sponsor
Emory University
Other
Eligibility
35 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 5, 2026, 10:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)

NCT06619678
View directory record Official record
Conditions
Healthy
Interventions
MK-8507, Islatravir
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 5, 2026, 10:54 AM EDT
Completed Phase 2 Interventional

Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV

NCT06538285
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Ketamine, Psychotherapy
Drug · Behavioral
Lead sponsor
Nicky Mehtani, MD, MPH
Other
Eligibility
18 Years to 69 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francicso, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 5, 2026, 10:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy Subjects

NCT02821338
View directory record Official record
Conditions
Healthy
Interventions
Lamotrigine Extended Release
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Sep 5, 2026, 10:54 AM EDT
Not listed Phase 1Phase 2 Interventional

The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19

NCT04798716
View directory record Official record
Conditions
Covid19, Novel Coronavirus Pneumonia, Acute Respiratory Distress Syndrome
Interventions
MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8)
Drug
Lead sponsor
AVEM HealthCare
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Panorama City, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Sep 5, 2026, 10:54 AM EDT
Completed Not applicable Interventional Results available

Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

NCT02846233
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
GLP1 receptor agonist, basal insulin, SGLT2 inhibitor, Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 5, 2026, 10:54 AM EDT
Withdrawn Not applicable Interventional

Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC)

NCT06603155
View directory record Official record
Conditions
Metastatic Head-and-neck Squamous-cell Carcinoma, Unresectable Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
Time restricted eating (TRE)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 5, 2026, 10:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of E-Cigarette Nicotine Content in Smokers (Nicotine Flux Study)

NCT04332926
View directory record Official record
Conditions
Electronic Cigarette Use
Interventions
Tobacco product administration and assessment, own brand cigarettes, Tobacco product administration and assessment, ECIG 30 Watts, 0 mg/ml nicotine, Tobacco product administration and assessment, ECIG 30 Watts, 8 mg/ml nicotine, Tobacco product administration and assessment, ECIG 30 Watts, 15 mg/ml nicotine, Tobacco product administration and assessment, ECIG 30 Watts, 30 mg/ml nicotine
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 5, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants

NCT02908685
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Placebo, Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 25 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Palo Alto, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 5, 2026, 10:54 AM EDT
Recruiting Phase 2 Interventional

Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History

NCT05446584
View directory record Official record
Conditions
Mild Cognitive Impairment, Amnestic Mild Cognitive Disorder, Amnestic Mild Cognitive Impairment, Mild Traumatic Brain Injury, Concussion, Brain
Interventions
High Definition Transcranial Direct Current Stimulation
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
55 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 5, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)

NCT00267748
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Sunitinib Malate Continuous Daily Dosing, Sunitinib Malate Schedule 4/2
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
156
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 114 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2011 · Synced Sep 5, 2026, 10:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose

NCT03586843
View directory record Official record
Conditions
Obesity
Interventions
JNJ-64565111
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 5, 2026, 10:54 AM EDT
Terminated Not applicable Interventional

Efficacy of Near Infrared Phototherapy in Type 2 Diabetic Neuropathy

NCT02798393
View directory record Official record
Conditions
Neuropathy
Interventions
Infrared Phototherapy, Sham
Other
Lead sponsor
Healthlight, LLC
Industry
Eligibility
25 Years to 90 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Topeka, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 5, 2026, 10:54 AM EDT
Completed Not applicable Interventional Results available

Transmagnetic Stimulation Pilot in Primary Progressive Aphasia

NCT05860647
View directory record Official record
Conditions
Primary Progressive Aphasia
Interventions
Intermittent theta burst stimulation
Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
40 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 5, 2026, 10:54 AM EDT